Form 4: Galectin Therapeutics Insider Sells Shares Under 10b5-1 Plan

Galectin Therapeutics reports that Chief Medical Officer Jamil Khurram sold 7,557 shares of common stock under a pre-arranged trading plan.

Summary

• Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc. (GALT), executed a transaction on June 23, 2026.
• This transaction involved the sale of 7,557 shares of common stock.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on February 2, 2026.
• The weighted average sale price for these shares was $3.14, with individual sales ranging from $3.10 to $3.17.
• Following this transaction, Khurram directly beneficially owns 0 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale was conducted under a pre-arranged Rule 10b5-1 plan, mitigating concerns of insider trading based on non-public information.

Negatives

• Insider selling of company stock can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established plan.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction by an insider.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common for executives to diversify holdings or manage personal finances without implying negative sentiment about the company's prospects. However, the market often scrutinizes such sales.

Stakeholder Impact

• Shareholders: The sale by a key executive might be observed, but the Rule 10b5-1 plan indicates it was pre-planned and not necessarily a reflection of negative company outlook.

Key Dates

Keywords

Galectin Therapeutics, GALT, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Chief Medical Officer, Beneficial Ownership